Mayo Clinic Gastroenterology and Hepatology | Strategic Alliance Partners

The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

RBX2660 is the first ever live microbiota therapeutic approved by the FDA.

RBX2660 is the first live microbiota therapeutic approved by the FDA.

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

There are several potential treatments on the horizon for C difficile infections.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

Dr. Simonetto is involved in several studies using artificial intelligence.

April 6 is Donate Life Living Donor Day, a day to promote liver donations.

For patients treated with DOACs, the investigators suggest temporarily interrupting treatment rather than continued use.